Genpact (G) Competitors $41.67 -0.53 (-1.25%) Closing price 08/7/2025 03:59 PM EasternExtended Trading$41.02 -0.66 (-1.57%) As of 08:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock G vs. CCRN, BR, GPN, JKHY, EXLS, WEX, EEFT, MMS, PAY, and WUShould you be buying Genpact stock or one of its competitors? The main competitors of Genpact include Cross Country Healthcare (CCRN), Broadridge Financial Solutions (BR), Global Payments (GPN), Jack Henry & Associates (JKHY), ExlService (EXLS), WEX (WEX), Euronet Worldwide (EEFT), Maximus (MMS), Paymentus (PAY), and Western Union (WU). Genpact vs. Its Competitors Cross Country Healthcare Broadridge Financial Solutions Global Payments Jack Henry & Associates ExlService WEX Euronet Worldwide Maximus Paymentus Western Union Cross Country Healthcare (NASDAQ:CCRN) and Genpact (NYSE:G) are related companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation. Which has more volatility and risk, CCRN or G? Cross Country Healthcare has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500. Comparatively, Genpact has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Which has stronger valuation & earnings, CCRN or G? Genpact has higher revenue and earnings than Cross Country Healthcare. Cross Country Healthcare is trading at a lower price-to-earnings ratio than Genpact, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCross Country Healthcare$1.19B0.34-$14.56M-$0.26-48.19Genpact$4.77B1.53$513.67M$2.9314.22 Is CCRN or G more profitable? Genpact has a net margin of 10.88% compared to Cross Country Healthcare's net margin of -0.70%. Genpact's return on equity of 22.35% beat Cross Country Healthcare's return on equity.Company Net Margins Return on Equity Return on Assets Cross Country Healthcare-0.70% 1.71% 1.22% Genpact 10.88%22.35%10.50% Does the media refer more to CCRN or G? In the previous week, Genpact had 15 more articles in the media than Cross Country Healthcare. MarketBeat recorded 23 mentions for Genpact and 8 mentions for Cross Country Healthcare. Genpact's average media sentiment score of 0.90 beat Cross Country Healthcare's score of 0.23 indicating that Genpact is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cross Country Healthcare 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Genpact 14 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders have more ownership in CCRN or G? 96.0% of Cross Country Healthcare shares are owned by institutional investors. Comparatively, 96.0% of Genpact shares are owned by institutional investors. 4.9% of Cross Country Healthcare shares are owned by insiders. Comparatively, 3.1% of Genpact shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts recommend CCRN or G? Cross Country Healthcare currently has a consensus target price of $17.93, indicating a potential upside of 43.10%. Genpact has a consensus target price of $49.75, indicating a potential upside of 19.38%. Given Cross Country Healthcare's higher probable upside, equities research analysts clearly believe Cross Country Healthcare is more favorable than Genpact.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cross Country Healthcare 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Genpact 0 Sell rating(s) 5 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.38 SummaryGenpact beats Cross Country Healthcare on 14 of the 16 factors compared between the two stocks. Get Genpact News Delivered to You Automatically Sign up to receive the latest news and ratings for G and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding G and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart G vs. The Competition Export to ExcelMetricGenpactIT Services IndustryComputer SectorNYSE ExchangeMarket Cap$7.38B$15.93B$29.51B$20.71BDividend Yield1.61%1.72%3.11%3.67%P/E Ratio14.2237.8450.8928.65Price / Sales1.5312.301,575.9069.00Price / Cash11.7324.1236.7223.59Price / Book3.084.577.314.32Net Income$513.67M$434.10M$803.33M$995.66M7 Day Performance-1.81%0.42%1.13%1.91%1 Month Performance-9.70%-8.82%-0.75%-0.54%1 Year Performance28.70%16.23%53,045.79%14.76% Genpact Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GGenpact3.7875 of 5 stars$41.67-1.3%$49.75+19.4%+29.1%$7.38B$4.77B14.22140,000News CoverageEarnings ReportHigh Trading VolumeCCRNCross Country Healthcare3.6755 of 5 stars$13.81+1.5%$17.93+29.8%-20.4%$452.69M$1.34B-26.068,205Earnings ReportGap DownBRBroadridge Financial Solutions4.5307 of 5 stars$252.54-0.5%$250.83-0.7%+25.6%$29.66B$6.77B37.9814,600Trending NewsEarnings ReportDividend IncreaseAnalyst ForecastHigh Trading VolumeGPNGlobal Payments4.9963 of 5 stars$84.69-1.2%$111.65+31.8%-17.7%$20.65B$10.10B13.6627,000Trending NewsEarnings ReportDividend AnnouncementAnalyst ForecastJKHYJack Henry & Associates4.6483 of 5 stars$175.38-0.6%$185.11+5.5%-1.2%$12.77B$2.32B29.887,170Positive NewsInsider TradeEXLSExlService4.4808 of 5 stars$42.22-1.5%$51.50+22.0%+23.6%$6.87B$1.90B31.9859,500Positive NewsWEXWEX4.2415 of 5 stars$175.86+0.1%$180.25+2.5%+0.5%$6.02B$2.63B22.236,500Positive NewsEEFTEuronet Worldwide4.57 of 5 stars$104.65+0.8%$123.83+18.3%-4.8%$4.53B$3.99B15.5010,600MMSMaximus3.3919 of 5 stars$72.91-0.7%$90.00+23.4%-10.7%$4.11B$5.31B14.4941,100Trending NewsEarnings ReportGap UpPAYPaymentus2.1527 of 5 stars$28.46-0.6%$36.80+29.3%+78.8%$3.56B$962.11M72.981,307Earnings ReportAnalyst ForecastAnalyst RevisionWUWestern Union3.7339 of 5 stars$8.43-1.7%$10.33+22.6%-30.4%$2.79B$4.21B3.159,100 Related Companies and Tools Related Companies Cross Country Healthcare Competitors Broadridge Financial Solutions Competitors Global Payments Competitors Jack Henry & Associates Competitors ExlService Competitors WEX Competitors Euronet Worldwide Competitors Maximus Competitors Paymentus Competitors Western Union Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:G) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genpact Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Genpact With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
